Over the last decade, the most successful clinical application in the field of SL is the development of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors in BRCA1/2-mutant breast and ovarian cancers (9). Here, PARP1 is linked to ovarian cancer.